Myris Therapeutics

Here is a fact about antibody drug conjugates that has quietly governed an entire corner of oncology for two decades. An ADC is, roughly, a guided missile: you take an antibody that knows how to find a tumor cell, and you bolt a toxic drug onto it so the poison rides to the target and spares everything else. The number of drug molecules you can bolt on is called the DAR - the drug-to-antibody ratio - and for years the practical ceiling has been about eight. Go higher and the antibody tends to clump, get cleared by the liver, or otherwise stop behaving like a missile and start behaving like a problem.

Myris Therapeutics, a company of about twenty-five people operating out of Pittsburgh, would like a word about that ceiling. Their platform attaches somewhere between 50 and 300 drug molecules per antibody. That is not a nicer version of eight. That is ten to a hundred times eight, which is the kind of gap that stops being a quantitative improvement and becomes a different category of thing entirely.

The way you get from eight to three hundred, it turns out, is not by finding a cleverer place to hang the drugs. It is by growing a polymer. Myris uses a technique called ATRP - atom transfer radical polymerization - to build a polymer "bottlebrush" directly on the antibody, and then decorates that brush with payload. Instead of a handful of hooks, you get a dense, controllable scaffold. It is the difference between hanging coats on a wall and hanging them on a coat rack you grew on the spot.

The thing about deep-tech origin stories is that the science is usually much older than the company. Myris did not spring from nowhere in 2025. It was previously BioHybrid Solutions, a company that used the same polymer-conjugation chemistry to build enzyme-based drug candidates - for gout, and for nerve-agent poisoning, of all things. The lab, the chemistry, and much of the intellectual DNA were already there. What changed was where they pointed it.

The ATRP foundation goes back further still, to more than a thousand publications and three decades of work at Carnegie Mellon University out of the lab of Dr. Krzysztof Matyjaszewski - one of the most cited chemists alive and a name that surfaces every autumn in Nobel Prize speculation. ATRP is the technique that made controlled polymer synthesis practical at scale. Myris' bet is that the same control that revolutionized materials science can revolutionize what you can attach to an antibody. When you have that much foundational research behind you, the interesting question is not whether the science works. It is whether anyone is bold enough to aim it at cancer.

Every cancer drug lives or dies by its therapeutic window - the gap between the dose that helps and the dose that harms. ADCs exist to widen that window by delivering poison precisely. Myris' argument is that if you can deliver far more poison per antibody, precisely, you can widen the window further: more payload where you want it, less collateral where you don't. It is either reckless or exactly right, and the honest answer is that clinical data will decide, not a press release.

The business shape is familiar for platform biotech. Myris is a B2B, research-stage company monetizing a proprietary technology and an internal pipeline - funded so far by seed capital, non-dilutive government money, and partnered programs. The reported funding is modest (a roughly $2.87M total, with a $200K seed tranche noted in late 2023), which makes the Department of Defense's backing of the lead program the more telling signal: the DoD does not typically write checks for chemistry that only works on a slide.

Who does Myris compete with? Effectively the entire modern ADC field - ImmunoGen, Seagen, the Daiichi Sankyo / AstraZeneca juggernaut behind Enhertu, Mersana, Sutro, and a long tail of next-generation conjugation startups. The difference Myris is selling is not a better antibody or a better target. It is a better answer to the question of how much you can carry, and what.